

# Global Tumor Necrosis Factor Inhibitors Drug Market Growth 2022-2028

<https://marketpublishers.com/r/GE6D781D90F8EN.html>

Date: January 2022

Pages: 127

Price: US\$ 3,660.00 (Single User License)

ID: GE6D781D90F8EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Tumor Necrosis Factor Inhibitors Drug will have significant change from previous year. According to our (LP Information) latest study, the global Tumor Necrosis Factor Inhibitors Drug market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Tumor Necrosis Factor Inhibitors Drug market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Tumor Necrosis Factor Inhibitors Drug market is expected at value of US\$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Tumor Necrosis Factor Inhibitors Drug market, reaching US\$ million by the year 2028. As for the Europe Tumor Necrosis Factor Inhibitors Drug landscape, Germany is projected to reach US\$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Tumor Necrosis Factor Inhibitors Drug players cover Apogenix, AryoGen Biopharma, Bionovis, and CASI Pharmaceuticals, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Necrosis Factor Inhibitors Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6

Cimzia (Certolizumab Pegol)

Enbrel (Etanercept)

Humira ( Adalimumab)

Otezla (Apremilast)

Remicade (Infliximab)

Simponi (Golimumab)

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

Clinic

Hospital

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding

detailed analysis of the prominent manufacturers in this market, include

Apogenix

AryoGen Biopharma

Bionovis

CASI Pharmaceuticals

Celltrion

Celgene Corporation

Delenex Therapeutics

Dexa Medica

EPIRUS Biopharmaceuticals

Janssen Biotech

GlaxoSmithKline

HanAll Biopharma

Intas Pharmaceuticals

LEO Pharma

LG Life Sciences

MedImmune

Momenta Pharmaceuticals

Novartis

PROBIOMED

Reliance Life Sciences

Sandoz

Samsung Bioepis

Sanofi-Aventis

Shanghai CP Guojian Pharmaceutical

Shanghai Pharmaceuticals

Sincere Pharmaceutical

Toyama Chemical

Tsumura

UCB

Zydus Cadila

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global Tumor Necrosis Factor Inhibitors Drug Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Tumor Necrosis Factor Inhibitors Drug by Geographic Region, 2017, 2022 & 2028
- 2.1.3 World Current & Future Analysis for Tumor Necrosis Factor Inhibitors Drug by Country/Region, 2017, 2022 & 2028

#### 2.2 Tumor Necrosis Factor Inhibitors Drug Segment by Type

- 2.2.1 Cimzia (Certolizumab Pegol)
- 2.2.2 Enbrel (Etanercept)
- 2.2.3 Humira ( Adalimumab)
- 2.2.4 Otezla (Apremilast)
- 2.2.5 Remicade (Infliximab)
- 2.2.6 Simponi (Golimumab)

#### 2.3 Tumor Necrosis Factor Inhibitors Drug Sales by Type

- 2.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2017-2022)
- 2.3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Type (2017-2022)
- 2.3.3 Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Type (2017-2022)

#### 2.4 Tumor Necrosis Factor Inhibitors Drug Segment by Application

- 2.4.1 Clinic
- 2.4.2 Hospital
- 2.4.3 Others

#### 2.5 Tumor Necrosis Factor Inhibitors Drug Sales by Application

- 2.5.1 Global Tumor Necrosis Factor Inhibitors Drug Sale Market Share by Application

(2017-2022)

2.5.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Application (2017-2022)

### **3 GLOBAL TUMOR NECROSIS FACTOR INHIBITORS DRUG BY COMPANY**

3.1 Global Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Company

3.1.1 Global Tumor Necrosis Factor Inhibitors Drug Annual Sales by Company (2020-2022)

3.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2020-2022)

3.2 Global Tumor Necrosis Factor Inhibitors Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2020-2022)

3.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2020-2022)

3.3 Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Company

3.4 Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Location Distribution

3.4.2 Players Tumor Necrosis Factor Inhibitors Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

### **4 WORLD HISTORIC REVIEW FOR TUMOR NECROSIS FACTOR INHIBITORS DRUG BY GEOGRAPHIC REGION**

4.1 World Historic Tumor Necrosis Factor Inhibitors Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Tumor Necrosis Factor Inhibitors Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Tumor Necrosis Factor Inhibitors Drug Annual Revenue by Geographic

## Region

### 4.2 World Historic Tumor Necrosis Factor Inhibitors Drug Market Size by Country/Region (2017-2022)

#### 4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Annual Sales by Country/Region (2017-2022)

#### 4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Annual Revenue by Country/Region

### 4.3 Americas Tumor Necrosis Factor Inhibitors Drug Sales Growth

### 4.4 APAC Tumor Necrosis Factor Inhibitors Drug Sales Growth

### 4.5 Europe Tumor Necrosis Factor Inhibitors Drug Sales Growth

### 4.6 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Growth

## 5 AMERICAS

### 5.1 Americas Tumor Necrosis Factor Inhibitors Drug Sales by Country

#### 5.1.1 Americas Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022)

#### 5.1.2 Americas Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022)

### 5.2 Americas Tumor Necrosis Factor Inhibitors Drug Sales by Type

### 5.3 Americas Tumor Necrosis Factor Inhibitors Drug Sales by Application

### 5.4 United States

### 5.5 Canada

### 5.6 Mexico

### 5.7 Brazil

## 6 APAC

### 6.1 APAC Tumor Necrosis Factor Inhibitors Drug Sales by Region

#### 6.1.1 APAC Tumor Necrosis Factor Inhibitors Drug Sales by Region (2017-2022)

#### 6.1.2 APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2017-2022)

### 6.2 APAC Tumor Necrosis Factor Inhibitors Drug Sales by Type

### 6.3 APAC Tumor Necrosis Factor Inhibitors Drug Sales by Application

### 6.4 China

### 6.5 Japan

### 6.6 South Korea

### 6.7 Southeast Asia

### 6.8 India

### 6.9 Australia

### 6.10 China Taiwan



## **7 EUROPE**

### 7.1 Europe Tumor Necrosis Factor Inhibitors Drug by Country

7.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022)

7.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022)

### 7.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type

### 7.3 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application

### 7.4 Germany

### 7.5 France

### 7.6 UK

### 7.7 Italy

### 7.8 Russia

## **8 MIDDLE EAST & AFRICA**

### 8.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug by Country

8.1.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022)

### 8.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type

### 8.3 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application

### 8.4 Egypt

### 8.5 South Africa

### 8.6 Israel

### 8.7 Turkey

### 8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

### 9.1 Market Drivers & Growth Opportunities

### 9.2 Market Challenges & Risks

### 9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

### 10.1 Raw Material and Suppliers

### 10.2 Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitors Drug

10.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug

10.4 Industry Chain Structure of Tumor Necrosis Factor Inhibitors Drug

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Tumor Necrosis Factor Inhibitors Drug Distributors

11.3 Tumor Necrosis Factor Inhibitors Drug Customer

## **12 WORLD FORECAST REVIEW FOR TUMOR NECROSIS FACTOR INHIBITORS DRUG BY GEOGRAPHIC REGION**

12.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Region

12.1.1 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Region (2023-2028)

12.1.2 Global Tumor Necrosis Factor Inhibitors Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Type

12.7 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Application

## **13 KEY PLAYERS ANALYSIS**

13.1 Apogenix

13.1.1 Apogenix Company Information

13.1.2 Apogenix Tumor Necrosis Factor Inhibitors Drug Product Offered

13.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Apogenix Main Business Overview

13.1.5 Apogenix Latest Developments

13.2 AryoGen Biopharma

13.2.1 AryoGen Biopharma Company Information

13.2.2 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Offered

13.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)

- 13.2.4 AryoGen Biopharma Main Business Overview
- 13.2.5 AryoGen Biopharma Latest Developments
- 13.3 Bionovis
  - 13.3.1 Bionovis Company Information
  - 13.3.2 Bionovis Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.3.4 Bionovis Main Business Overview
  - 13.3.5 Bionovis Latest Developments
- 13.4 CASI Pharmaceuticals
  - 13.4.1 CASI Pharmaceuticals Company Information
  - 13.4.2 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.4.4 CASI Pharmaceuticals Main Business Overview
  - 13.4.5 CASI Pharmaceuticals Latest Developments
- 13.5 Celltrion
  - 13.5.1 Celltrion Company Information
  - 13.5.2 Celltrion Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.5.4 Celltrion Main Business Overview
  - 13.5.5 Celltrion Latest Developments
- 13.6 Celgene Corporation
  - 13.6.1 Celgene Corporation Company Information
  - 13.6.2 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.6.4 Celgene Corporation Main Business Overview
  - 13.6.5 Celgene Corporation Latest Developments
- 13.7 Delenex Therapeutics
  - 13.7.1 Delenex Therapeutics Company Information
  - 13.7.2 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.7.4 Delenex Therapeutics Main Business Overview
  - 13.7.5 Delenex Therapeutics Latest Developments
- 13.8 Dexa Medica
  - 13.8.1 Dexa Medica Company Information

- 13.8.2 DEXA Medica Tumor Necrosis Factor Inhibitors Drug Product Offered
- 13.8.3 DEXA Medica Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.8.4 DEXA Medica Main Business Overview
- 13.8.5 DEXA Medica Latest Developments
- 13.9 EPIRUS Biopharmaceuticals
  - 13.9.1 EPIRUS Biopharmaceuticals Company Information
  - 13.9.2 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.9.4 EPIRUS Biopharmaceuticals Main Business Overview
  - 13.9.5 EPIRUS Biopharmaceuticals Latest Developments
- 13.10 Janssen Biotech
  - 13.10.1 Janssen Biotech Company Information
  - 13.10.2 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.10.4 Janssen Biotech Main Business Overview
  - 13.10.5 Janssen Biotech Latest Developments
- 13.11 GlaxoSmithKline
  - 13.11.1 GlaxoSmithKline Company Information
  - 13.11.2 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.11.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.11.4 GlaxoSmithKline Main Business Overview
  - 13.11.5 GlaxoSmithKline Latest Developments
- 13.12 HanAll Biopharma
  - 13.12.1 HanAll Biopharma Company Information
  - 13.12.2 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.12.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.12.4 HanAll Biopharma Main Business Overview
  - 13.12.5 HanAll Biopharma Latest Developments
- 13.13 Intas Pharmaceuticals
  - 13.13.1 Intas Pharmaceuticals Company Information
  - 13.13.2 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.13.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)

- 13.13.4 Intas Pharmaceuticals Main Business Overview
- 13.13.5 Intas Pharmaceuticals Latest Developments
- 13.14 LEO Pharma
  - 13.14.1 LEO Pharma Company Information
  - 13.14.2 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.14.3 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.14.4 LEO Pharma Main Business Overview
  - 13.14.5 LEO Pharma Latest Developments
- 13.15 LG Life Sciences
  - 13.15.1 LG Life Sciences Company Information
  - 13.15.2 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.15.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.15.4 LG Life Sciences Main Business Overview
  - 13.15.5 LG Life Sciences Latest Developments
- 13.16 MedImmune
  - 13.16.1 MedImmune Company Information
  - 13.16.2 MedImmune Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.16.3 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.16.4 MedImmune Main Business Overview
  - 13.16.5 MedImmune Latest Developments
- 13.17 Momenta Pharmaceuticals
  - 13.17.1 Momenta Pharmaceuticals Company Information
  - 13.17.2 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.17.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.17.4 Momenta Pharmaceuticals Main Business Overview
  - 13.17.5 Momenta Pharmaceuticals Latest Developments
- 13.18 Novartis
  - 13.18.1 Novartis Company Information
  - 13.18.2 Novartis Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.18.3 Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.18.4 Novartis Main Business Overview
  - 13.18.5 Novartis Latest Developments
- 13.19 PROBIOMED

- 13.19.1 PROBIOMED Company Information
- 13.19.2 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Offered
- 13.19.3 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.19.4 PROBIOMED Main Business Overview
- 13.19.5 PROBIOMED Latest Developments
- 13.20 Reliance Life Sciences
  - 13.20.1 Reliance Life Sciences Company Information
  - 13.20.2 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.20.3 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.20.4 Reliance Life Sciences Main Business Overview
  - 13.20.5 Reliance Life Sciences Latest Developments
- 13.21 Sandoz
  - 13.21.1 Sandoz Company Information
  - 13.21.2 Sandoz Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.21.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.21.4 Sandoz Main Business Overview
  - 13.21.5 Sandoz Latest Developments
- 13.22 Samsung Bioepis
  - 13.22.1 Samsung Bioepis Company Information
  - 13.22.2 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.22.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.22.4 Samsung Bioepis Main Business Overview
  - 13.22.5 Samsung Bioepis Latest Developments
- 13.23 Sanofi-Aventis
  - 13.23.1 Sanofi-Aventis Company Information
  - 13.23.2 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.23.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.23.4 Sanofi-Aventis Main Business Overview
  - 13.23.5 Sanofi-Aventis Latest Developments
- 13.24 Shanghai CP Guojian Pharmaceutical
  - 13.24.1 Shanghai CP Guojian Pharmaceutical Company Information
  - 13.24.2 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Offered
  - 13.24.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug



## Sales, Revenue, Price and Gross Margin (2020-2022)

13.24.4 Shanghai CP Guojian Pharmaceutical Main Business Overview

13.24.5 Shanghai CP Guojian Pharmaceutical Latest Developments

## 13.25 Shanghai Pharmaceuticals

13.25.1 Shanghai Pharmaceuticals Company Information

13.25.2 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered

13.25.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.25.4 Shanghai Pharmaceuticals Main Business Overview

13.25.5 Shanghai Pharmaceuticals Latest Developments

## 13.26 Simcere Pharmaceutical

13.26.1 Simcere Pharmaceutical Company Information

13.26.2 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Offered

13.26.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.26.4 Simcere Pharmaceutical Main Business Overview

13.26.5 Simcere Pharmaceutical Latest Developments

## 13.27 Toyama Chemical

13.27.1 Toyama Chemical Company Information

13.27.2 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Offered

13.27.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.27.4 Toyama Chemical Main Business Overview

13.27.5 Toyama Chemical Latest Developments

## 13.28 Tsumura

13.28.1 Tsumura Company Information

13.28.2 Tsumura Tumor Necrosis Factor Inhibitors Drug Product Offered

13.28.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.28.4 Tsumura Main Business Overview

13.28.5 Tsumura Latest Developments

## 13.29 UCB

13.29.1 UCB Company Information

13.29.2 UCB Tumor Necrosis Factor Inhibitors Drug Product Offered

13.29.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.29.4 UCB Main Business Overview

13.29.5 UCB Latest Developments

13.30 Zydus Cadila

13.30.1 Zydus Cadila Company Information

13.30.2 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Offered

13.30.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.30.4 Zydus Cadila Main Business Overview

13.30.5 Zydus Cadila Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**



## List Of Tables

### LIST OF TABLES

Table 1. Tumor Necrosis Factor Inhibitors Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)

Table 2. Tumor Necrosis Factor Inhibitors Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)

Table 3. Major Players of Cimzia (Certolizumab Pegol)

Table 4. Major Players of Enbrel (Etanercept)

Table 5. Major Players of Humira ( Adalimumab)

Table 6. Major Players of Otezla (Apremilast)

Table 7. Major Players of Remicade (Infliximab)

Table 8. Major Players of Simponi (Golimumab)

Table 9. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)

Table 10. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2017-2022)

Table 11. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2022) & (\$ million)

Table 12. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2017-2022)

Table 13. Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Type (2017-2022) & (USD/Pcs)

Table 14. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)

Table 15. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2022)

Table 16. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2022)

Table 17. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2017-2022)

Table 18. Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Application (2017-2022) & (USD/Pcs)

Table 19. Global Tumor Necrosis Factor Inhibitors Drug Sales by Company (2020-2022) & (K Pcs)

Table 20. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2020-2022)

Table 21. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Company

(2020-2022) (\$ Millions)

Table 22. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2020-2022)

Table 23. Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Company (2020-2022) & (USD/Pcs)

Table 24. Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Producing Area Distribution and Sales Area

Table 25. Players Tumor Necrosis Factor Inhibitors Drug Products Offered

Table 26. Tumor Necrosis Factor Inhibitors Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Tumor Necrosis Factor Inhibitors Drug Sales by Geographic Region (2017-2022) & (K Pcs)

Table 30. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share Geographic Region (2017-2022)

Table 31. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 32. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Geographic Region (2017-2022)

Table 33. Global Tumor Necrosis Factor Inhibitors Drug Sales by Country/Region (2017-2022) & (K Pcs)

Table 34. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country/Region (2017-2022)

Table 35. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Country/Region (2017-2022) & (\$ millions)

Table 36. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country/Region (2017-2022)

Table 37. Americas Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022) & (K Pcs)

Table 38. Americas Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2017-2022)

Table 39. Americas Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022) & (\$ Millions)

Table 40. Americas Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2017-2022)

Table 41. Americas Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)

Table 42. Americas Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type

(2017-2022)

Table 43. Americas Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)

Table 44. Americas Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2022)

Table 45. APAC Tumor Necrosis Factor Inhibitors Drug Sales by Region (2017-2022) & (K Pcs)

Table 46. APAC Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2017-2022)

Table 47. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2017-2022) & (\$ Millions)

Table 48. APAC Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2017-2022)

Table 49. APAC Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)

Table 50. APAC Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2017-2022)

Table 51. APAC Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)

Table 52. APAC Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2022)

Table 53. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022) & (K Pcs)

Table 54. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2017-2022)

Table 55. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022) & (\$ Millions)

Table 56. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2017-2022)

Table 57. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)

Table 58. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2017-2022)

Table 59. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)

Table 60. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2022)

Table 61. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022) & (K Pcs)

Table 62. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2017-2022)

Table 63. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022) & (\$ Millions)

Table 64. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2017-2022)

Table 65. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)

Table 66. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2017-2022)

Table 67. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)

Table 68. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2022)

Table 69. Key Market Drivers & Growth Opportunities of Tumor Necrosis Factor Inhibitors Drug

Table 70. Key Market Challenges & Risks of Tumor Necrosis Factor Inhibitors Drug

Table 71. Key Industry Trends of Tumor Necrosis Factor Inhibitors Drug

Table 72. Tumor Necrosis Factor Inhibitors Drug Raw Material

Table 73. Key Suppliers of Raw Materials

Table 74. Tumor Necrosis Factor Inhibitors Drug Distributors List

Table 75. Tumor Necrosis Factor Inhibitors Drug Customer List

Table 76. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 77. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Forecast by Region

Table 78. Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 79. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share Forecast by Region (2023-2028)

Table 80. Americas Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 81. Americas Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 82. APAC Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 83. APAC Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 84. Europe Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country

(2023-2028) & (K Pcs)

Table 85. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 86. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 87. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 88. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Type (2023-2028) & (K Pcs)

Table 89. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Type (2023-2028)

Table 90. Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 91. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share Forecast by Type (2023-2028)

Table 92. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Application (2023-2028) & (K Pcs)

Table 93. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Application (2023-2028)

Table 94. Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 95. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share Forecast by Application (2023-2028)

Table 96. Apogenix Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 97. Apogenix Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 98. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 99. Apogenix Main Business

Table 100. Apogenix Latest Developments

Table 101. AryoGen Biopharma Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 102. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 103. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 104. AryoGen Biopharma Main Business

Table 105. AryoGen Biopharma Latest Developments

Table 106. Bionovis Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors



- Table 107. Bionovis Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 108. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 109. Bionovis Main Business
- Table 110. Bionovis Latest Developments
- Table 111. CASI Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 112. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 113. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 114. CASI Pharmaceuticals Main Business
- Table 115. CASI Pharmaceuticals Latest Developments
- Table 116. Celltrion Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 117. Celltrion Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 118. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 119. Celltrion Main Business
- Table 120. Celltrion Latest Developments
- Table 121. Celgene Corporation Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 122. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 123. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 124. Celgene Corporation Main Business
- Table 125. Celgene Corporation Latest Developments
- Table 126. Delenex Therapeutics Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 127. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 128. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 129. Delenex Therapeutics Main Business
- Table 130. Delenex Therapeutics Latest Developments
- Table 131. Dixa Medica Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 132. Dixa Medica Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 133. Dixa Medica Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue

(\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 134. DEXA Medica Main Business

Table 135. DEXA Medica Latest Developments

Table 136. EPIRUS Biopharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 137. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 138. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 139. EPIRUS Biopharmaceuticals Main Business

Table 140. EPIRUS Biopharmaceuticals Latest Developments

Table 141. Janssen Biotech Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 142. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 143. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 144. Janssen Biotech Main Business

Table 145. Janssen Biotech Latest Developments

Table 146. GlaxoSmithKline Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 147. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 148. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 149. GlaxoSmithKline Main Business

Table 150. GlaxoSmithKline Latest Developments

Table 151. HanAll Biopharma Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 152. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 153. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 154. HanAll Biopharma Main Business

Table 155. HanAll Biopharma Latest Developments

Table 156. Intas Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 157. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 158. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 159. Intas Pharmaceuticals Main Business

- Table 160. Intas Pharmaceuticals Latest Developments
- Table 161. LEO Pharma Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 162. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 163. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 164. LEO Pharma Main Business
- Table 165. LEO Pharma Latest Developments
- Table 166. LG Life Sciences Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 167. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 168. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 169. LG Life Sciences Main Business
- Table 170. LG Life Sciences Latest Developments
- Table 171. MedImmune Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 172. MedImmune Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 173. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 174. MedImmune Main Business
- Table 175. MedImmune Latest Developments
- Table 176. Momenta Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 177. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 178. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 179. Momenta Pharmaceuticals Main Business
- Table 180. Momenta Pharmaceuticals Latest Developments
- Table 181. Novartis Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 182. Novartis Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 183. Novartis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 184. Novartis Main Business
- Table 185. Novartis Latest Developments
- Table 186. PROBIOMED Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors



- Table 187. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 188. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 189. PROBIOMED Main Business
- Table 190. PROBIOMED Latest Developments
- Table 191. Reliance Life Sciences Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 192. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 193. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 194. Reliance Life Sciences Main Business
- Table 195. Reliance Life Sciences Latest Developments
- Table 196. Sandoz Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 197. Sandoz Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 198. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 199. Sandoz Main Business
- Table 200. Sandoz Latest Developments
- Table 201. Samsung Bioepis Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 202. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 203. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 204. Samsung Bioepis Main Business
- Table 205. Samsung Bioepis Latest Developments
- Table 206. Sanofi-Aventis Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 207. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 208. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 209. Sanofi-Aventis Main Business
- Table 210. Sanofi-Aventis Latest Developments
- Table 211. Shanghai CP Guojian Pharmaceutical Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
- Table 212. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Offered
- Table 213. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors

Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 214. Shanghai CP Guojian Pharmaceutical Main Business

Table 215. Shanghai CP Guojian Pharmaceutical Latest Developments

Table 216. Shanghai Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 217. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 218. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 219. Shanghai Pharmaceuticals Main Business

Table 220. Shanghai Pharmaceuticals Latest Developments

Table 221. Simcere Pharmaceutical Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 222. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 223. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 224. Simcere Pharmaceutical Main Business

Table 225. Simcere Pharmaceutical Latest Developments

Table 226. Toyama Chemical Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 227. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 228. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 229. Toyama Chemical Main Business

Table 230. Toyama Chemical Latest Developments

Table 231. Tsumura Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 232. Tsumura Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 233. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 234. Tsumura Main Business

Table 235. Tsumura Latest Developments

Table 236. UCB Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 237. UCB Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 238. UCB Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 239. UCB Main Business

Table 240. UCB Latest Developments

Table 241. Zydus Cadila Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors

Table 242. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Offered

Table 243. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 244. Zydus Cadila Main Business

Table 245. Zydus Cadila Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Tumor Necrosis Factor Inhibitors Drug
- Figure 2. Tumor Necrosis Factor Inhibitors Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate 2017-2028 (K Pcs)
- Figure 7. Global Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. Tumor Necrosis Factor Inhibitors Drug Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Cimzia (Certolizumab Pegol)
- Figure 10. Product Picture of Enbrel (Etanercept)
- Figure 11. Product Picture of Humira ( Adalimumab)
- Figure 12. Product Picture of Otezla (Apremilast)
- Figure 13. Product Picture of Remicade (Infliximab)
- Figure 14. Product Picture of Simponi (Golimumab)
- Figure 15. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2021
- Figure 16. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2017-2022)
- Figure 17. Tumor Necrosis Factor Inhibitors Drug Consumed in Clinic
- Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Market: Clinic (2017-2022) & (K Pcs)
- Figure 19. Tumor Necrosis Factor Inhibitors Drug Consumed in Hospital
- Figure 20. Global Tumor Necrosis Factor Inhibitors Drug Market: Hospital (2017-2022) & (K Pcs)
- Figure 21. Tumor Necrosis Factor Inhibitors Drug Consumed in Others
- Figure 22. Global Tumor Necrosis Factor Inhibitors Drug Market: Others (2017-2022) & (K Pcs)
- Figure 23. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2022)
- Figure 24. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application in 2021
- Figure 25. Tumor Necrosis Factor Inhibitors Drug Revenue Market by Company in 2021

(\$ Million)

Figure 26. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company in 2021

Figure 27. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Geographic Region (2017-2022)

Figure 28. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Geographic Region in 2021

Figure 29. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2017-2022)

Figure 30. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country/Region in 2021

Figure 31. Americas Tumor Necrosis Factor Inhibitors Drug Sales 2017-2022 (K Pcs)

Figure 32. Americas Tumor Necrosis Factor Inhibitors Drug Revenue 2017-2022 (\$ Millions)

Figure 33. APAC Tumor Necrosis Factor Inhibitors Drug Sales 2017-2022 (K Pcs)

Figure 34. APAC Tumor Necrosis Factor Inhibitors Drug Revenue 2017-2022 (\$ Millions)

Figure 35. Europe Tumor Necrosis Factor Inhibitors Drug Sales 2017-2022 (K Pcs)

Figure 36. Europe Tumor Necrosis Factor Inhibitors Drug Revenue 2017-2022 (\$ Millions)

Figure 37. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales 2017-2022 (K Pcs)

Figure 38. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue 2017-2022 (\$ Millions)

Figure 39. Americas Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country in 2021

Figure 40. Americas Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country in 2021

Figure 41. United States Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 42. Canada Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 43. Mexico Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 44. Brazil Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 45. APAC Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region in 2021

Figure 46. APAC Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by

## Regions in 2021

Figure 47. China Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 48. Japan Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 49. South Korea Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 50. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 51. India Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 52. Australia Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 53. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country in 2021

Figure 54. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country in 2021

Figure 55. Germany Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 56. France Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 57. UK Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 58. Italy Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 59. Russia Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 60. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country in 2021

Figure 61. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country in 2021

Figure 62. Egypt Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 63. South Africa Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 64. Israel Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 65. Turkey Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 66. GCC Country Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 67. Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitors Drug in 2021

Figure 68. Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug

Figure 69. Industry Chain Structure of Tumor Necrosis Factor Inhibitors Drug

Figure 70. Channels of Distribution

Figure 71. Distributors Profiles



## I would like to order

Product name: Global Tumor Necrosis Factor Inhibitors Drug Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/GE6D781D90F8EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE6D781D90F8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970